

the disclosure of which is incorporated herein by reference (WO 00/20609). A chinchilla nasopharyngeal colonization model has been developed specifically to demonstrate vaccine efficacy of adhesins (ref. 14) and the rHMW proteins are protective in this model as described in the aforementioned copending United States Patent Application No. 09/167,568. The rHMW1A and rHMW2A proteins were shown to afford equivalent protection to each other and the rHMW1A protein was chosen for further vaccine studies. In this application, rHMW refers to the recombinant HMW1A protein from NTHi strain 12, although the corresponding recombinant HMW1A protein from other NTHi strains and the corresponding rHMW2A protein from NTHi strains may be employed for the rHMW. The corresponding naturally-occurring proteins also may be employed."

Please replace the paragraph beginning at page 5, line 23, with the following rewritten paragraph:

"The immunogenic composition of the invention may be further formulated with an adjuvant. Such adjuvant for use in the present invention may include (but not limited to) aluminum phosphate, aluminum hydroxide, QS21 (trademark for a saponin adjuvant isolated from the bark of the Quillaja saponaria tree), QUIL A (trademark for a complex mixture of saponins from Quillaja saponaria and carbohydrates), derivatives and components thereof, ISCOM matrix, calcium phosphate, calcium hydroxide, zinc hydroxide, a glycolipid analog, an octadecyl ester of an amino acid, a muramyl dipeptide, polyphosphazene, ISCOPREP (trademark for a purified form of saponins derived from Quillaja saponaria), DC-CHOL (trademark of 3 b-(N-(N',N'-dimethyl aminomethane)-carbamoyl) cholesterol, DDBA (trademark of dimethyldioctadecylammonium bromide) and a lipoprotein and other adjuvants, including bacterial toxins, components and derivatives thereof as described, for example, in USAN 08/258,228 filed June 10, 1994, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference (WO 95/34323). Under particular circumstances, adjuvants that induce a Th1 response are desirable. Advantageous combinations of

B 3